Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11208829,response rate,The response rate and duration of response based on the time of the first dose of study drug for all responders (median of 6.9 months with a range of 2.7 to more than 46.1 months) were not statistically different between the two doses.,Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11208829/),month,6.9,55160,DB00004,Denileukin diftitox
,9427692,maximum tolerated dose,"The dose-limiting toxicity was asthenia, establishing the maximum tolerated dose of 27 micrograms/kg/day.",Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9427692/),[μg] / [d·kg],27,70776,DB00004,Denileukin diftitox
,9427692,time to response,The median time to response was 2 months and the duration of response was 2 to 39+ months.,Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9427692/),month,2,70777,DB00004,Denileukin diftitox
,9427692,duration of response,The median time to response was 2 months and the duration of response was 2 to 39+ months.,Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9427692/),month,2 to 39,70778,DB00004,Denileukin diftitox
,9427692,MTD,DAB389IL-2 is well tolerated with an MTD of 27 micrograms/kg/day.,Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9427692/),[μg] / [d·kg],27,70779,DB00004,Denileukin diftitox
,11707860,IC(50),"DAB(486)IL-2, in which the native receptor-binding domain of diphtheria toxin was replaced with the full-length interleukin-2 (IL-2) gene, was capable of intoxicating high-affinity IL-2 receptor-bearing cells in vitro with an IC(50) of 10(-10) M; whereas, cells lacking the full component of the high-affinity IL-2 receptor (p55, p75, p64) were relatively resistant (IC(50) of 10(-8) M).","DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707860/),M,10(-10),273894,DB00004,Denileukin diftitox
,11707860,IC(50),"DAB(486)IL-2, in which the native receptor-binding domain of diphtheria toxin was replaced with the full-length interleukin-2 (IL-2) gene, was capable of intoxicating high-affinity IL-2 receptor-bearing cells in vitro with an IC(50) of 10(-10) M; whereas, cells lacking the full component of the high-affinity IL-2 receptor (p55, p75, p64) were relatively resistant (IC(50) of 10(-8) M).","DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707860/),M,10(-8),273895,DB00004,Denileukin diftitox
